Endocrine Aspects of Hypertension

  • H. Vetter
  • W. Vetter


Around the turn of the century, Tigerstedt and Bergman produced hypertension in dogs by injecting a renal extract that they called renin.43 Decades later, in their classic experiments, Goldblatt et al. succeeded in demonstrating a relationship between experimentally induced stenosis of the renal artery and hypertension.23 Page and Helmer were the first to demonstrate that renin is an enzyme that acts on another substance to yield a vasoactive agent.36 Similar observations were reported by Braun-Menéndez.9 Later, the structural analysis of angiotensin II was successful, followed in turn by its synthesis.


Primary Aldosteronism Plasma Aldosterone Adrenal Vein Renin Secretion Plasma Aldosterone Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


Renin-Angiotensin-Aldosterone System

  1. 1.
    Aiken JW, Vane JR (1970) The renin-angiotensin system: Inhibition of converting enzyme in isolated tissues. Nature 228: 30–34PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson RC, Herbert PN, Mulrow PJ (1968) A comparison of properties of renin obtained from the kidney and uterus of the rabbit. Am J Physiol 215: 774–778PubMedGoogle Scholar
  3. 3.
    Bakkle YS (1971) Inhibition of angiotensin I converting enzyme by venom peptides. Brit J Pharmacol 43: 252–254Google Scholar
  4. 4.
    Bayard F, Cooke CR, Tiller DJ, Beitins IZ, Kowarski A, Walker WG, Migeon CJ (1971) The regulation of aldosterone secretion in anephric man. J Clin Invest 50: 1585–1595PubMedCrossRefGoogle Scholar
  5. 5.
    Biron P, Huggins CG (1968) Pulmonary activation of synthetic angiotensin 1. Life Sci 7: 965–970PubMedCrossRefGoogle Scholar
  6. 6.
    Blaine EH, David JO, Witty RT (1970) Renin re-lease after hemorrhage and after suprarenal aortic constriction in dogs without sodium delivery to the macula densa. Circ Res 27: 1081–1089PubMedGoogle Scholar
  7. 7.
    Blaine EH, David JO, Prewitt RL (1971) Evidence for a renal vascular receptor in control of renin secretion. Am J Physiol 220: 1593–1597PubMedGoogle Scholar
  8. 8.
    Blair-West JR, Coghlan JP, Denton DA, Funder JW, Scoggins BA, Wright RD (1971) The effect of the heptapeptide (2–8) and hexapeptide (3–8) fragments of angiotensin II on aldosterone secretion. J Clin Endocrinol 32: 575–578CrossRefGoogle Scholar
  9. 9.
    Braun-Menéndez E, Fasciolo JC, Leloir LF, Munoz JM (1940) The substance causing renal hypertension. J Physiol 98:283ffGoogle Scholar
  10. 10.
    Brubacher ES, Vander AJ (1968) Sodium deprivation and renin secretion in unanesthetized dogs. Am J Physiol 214: 15–21PubMedGoogle Scholar
  11. 11.
    Brunner HR, Baer L, Sealey JE, Ledingham JGG, Laragh JH (1970) The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest 49: 2128–2138PubMedCrossRefGoogle Scholar
  12. 12.
    Burton J, Poulsen K, Haber E (1975) Competitive inhibitors of renin: Inhibitors effective at physiological pH. Biochemistry 14: 3892–3898PubMedCrossRefGoogle Scholar
  13. 13.
    Capelli JP, Wesson LG, Aponte GE (1968) Characterization and source of a renin-like enzyme in anephric humans. J Clin Endocrinol 28: 221–230CrossRefGoogle Scholar
  14. 14.
    Carretero OA, Houle JA (1970) A comparison of renin obtained from pregnant uterus and kidney of the dog. Am J Physiol, 218: 689–692PubMedGoogle Scholar
  15. 15.
    Cooke CR, Horvath JS, Moore MA, Bledsoe T, Walker WG (1973) Modulation of plasma aldosterone concentration by plasma potassium in anephric man in the absence of a change in potassium balance. J Clin Invest 52: 3028–3032PubMedCrossRefGoogle Scholar
  16. 16.
    Davis JO, Urquhart J, Higgins A (1963) The effects of alteration of plasma sodium and potassium concentration on aldosterone secretion. J Clin Invest 42: 597–609PubMedCrossRefGoogle Scholar
  17. 17.
    Deodhar SD, Haas E, Goldblatt H (1964) Production of antirenin to homologous renin and its effect on experimental renal hypertension. J Exp Med 119: 425–432PubMedCrossRefGoogle Scholar
  18. 18.
    Dluhy RG, Axelrod L, Underwood RH, Williams GH (1972) Studies on the control of plasma aldosterone concentration in normal man. II. Effect of dietary potassium and acute potassium infusion. J Clin Invest 51: 1950–1957PubMedCrossRefGoogle Scholar
  19. 19.
    Edelman R, Hartcroft PM (1961) Localization of renin in juxtaglomerular cells of rabbit and dog through the use of the fluorescent-antibody technique. Circ Res 9: 1069–1077Google Scholar
  20. 20.
    Ferreira SH (1965) A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jajaraca. Brit J Pharmacol Chemother 24: 163–169Google Scholar
  21. 21.
    Ferris TF, Gordon P, Mulrow PJ (1967) Rabbit uterus as a source of renin. Am J Physiol 212: 698–706PubMedGoogle Scholar
  22. 22.
    Ganten D, Marquez-Julio A, Granger P, Hayduk K, Karsunky KP, Boucher R, Genest J (1971) Renin in dog brain. Am J Physiol 221: 1733–1737PubMedGoogle Scholar
  23. 23.
    Goldblatt H, Lynch J, Hanzal RF, Summerville WW (1934) Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59: 347–379PubMedCrossRefGoogle Scholar
  24. 24.
    Goodfriend T, Allman D, Kent K, Dempsey P, Cooper T (1971) Angiotensin’s inotropic and mitochondrial effects. Clin Res 19: 316Google Scholar
  25. 25.
    Goormaghtigh N (1939) Existence of an endocrine gland in the media of the renal arterioles. Proc Soc Exp Biol Med 42: 688–689Google Scholar
  26. 26.
    Granger P, Dahlheim H, Thurau K (1972) Enzyme activities of the single juxtaglomerular apparatus in the rat kidney. Kidney Int 1: 78–88PubMedCrossRefGoogle Scholar
  27. 27.
    Gross F, Schaechtelin G, Ziegler M, Berger M (1964) A renin-like substance in the placenta and uterus of the rabbit. Lancet 1: 914–916PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson JA, Davis JO, Witty RT (1971) Effect of the catecholamines and renal nerve stimulation on renin release in the nonfiltering kidney. Circ Res 29: 646–653PubMedGoogle Scholar
  29. 29.
    Michelakis AM, Candle J, Liddle GW (1969) In vitro stimulation of renin production by epinephrine, norepinephrine, and cyclic AMP. Proc Soc Exp Biol Med 130: 748–753PubMedGoogle Scholar
  30. 30.
    Müller J, Barajas L (1972) Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J Ultrastruct Res 41: 533–549PubMedCrossRefGoogle Scholar
  31. 31.
    Ng KKF, Vane JR (1967) Conversion of angiotensin I to angiotensin II. Nature 216: 762–766PubMedCrossRefGoogle Scholar
  32. 32.
    Ng KKF, Vane JR (1970) Some properties of angiotensin converting enzyme in the lung in vivo. Nature 225: 1142–1144PubMedCrossRefGoogle Scholar
  33. 33.
    Nilson O (1965) The adrenergic innervation of the kidney. J Lab Invest 14: 1392–1395Google Scholar
  34. 34.
    Igaard K (1975) Plasma aldosterone in anephric and non-nephrectomized dialysis patients in relation to changes in plasma potassium without change in total potassium balance. Acta Med Scand 198: 213–218Google Scholar
  35. 35.
    Olgaard K, Madson S, Hammer M (1977) The adrenocortical response to angiotensin II infusion in anephric and non-nephrectomized patients on regular hemodialysis. Acta Med Scand 202: 213–219PubMedCrossRefGoogle Scholar
  36. 36.
    Page IH, Helmer OM (1940) A crystalline pressure substance (angiotensin) resulting from the reaction between renin and renin activator. J Exp Med 71: 29PubMedCrossRefGoogle Scholar
  37. 37.
    Poulson K, Burton J, Haber E (1973) Competitive inhibitors of renin. Biochemistry 12: 3877–3882CrossRefGoogle Scholar
  38. 38.
    Romero JC, Hoobler SW, Kozak TJ, Warzynski RJ (1973) Effect of antirenin on blood pressure of rabbits with experimental renal hypertension. Am J Physiol 225: 810–817PubMedGoogle Scholar
  39. 39.
    Rosset E, Veyrat R (1971) Release of renin by human kidney slices: In vitro effect of angiotensin II, norepinephrine, and aldosterone. Rev Eur Etud Clin Biol 16: 792–794PubMedGoogle Scholar
  40. 40.
    Ryan JW (1967) Renin-like enzyme in the adrenal gland. Science 158: 1589–1590PubMedCrossRefGoogle Scholar
  41. 41.
    Shade RE, Davis JO, Johnson JA, Witty RT (1972) Effects of renal arterial infusion of sodium and potassium on renin secretion in the dog. Circ Res 31: 719–727PubMedGoogle Scholar
  42. 42.
    Tagawe H, Vander AJ, Bonjour JP, Malvin RL (1971) Inhibition of renin secretion by vasopressin in anesthetized sodium-deprived dogs. Am J Physiol 220: 949–951Google Scholar
  43. 43.
    Tigerstedt R, Bergman PG (1898) Niere und Kreislauf. Scand Arch Physiol 8: 223–271Google Scholar
  44. 44.
    Tobian L, Tomboulian A, Janacek J (1959) The effect of high perfusion pressures on the granulation of juxtaglomerular cells in an isolated kidney. J Clin Invest 38: 605–610PubMedCrossRefGoogle Scholar
  45. 45.
    Thurau K, Dahlheim H, Grüner A, Mason J, Granger P (1972) Activation of renin in the single juxtaglomerular apparatus by sodium chloride in the tubular fluid at the macula densa. Circ Res 30 (Suppl 2): 182–186Google Scholar
  46. 46.
    Vander A J, Miller R (1964) Control of renin secretion in the anesthetized dog. Am J Physiol 207: 537–546PubMedGoogle Scholar
  47. 47.
    Vander A J (1965) Effect of catecholamines and renal nerves on renin secretion in anesthetized dogs. Am J Physiol 209: 659–662PubMedGoogle Scholar
  48. 48.
    Vetter W, Zâruba K, Armbruster H, Beckerhoff R, Reck G, Siegenthaler W (1974) Control of plasma aldosterone in supine anephric man. Clin Endocrinol 3: 411–419CrossRefGoogle Scholar
  49. 49.
    Vetter W, Zâruba K, Armbruster H, Beckerhoff R, Uhlschmid G, Furrer J, Siegenthaler W (1970) Control of plasma aldosterone in terminal renal failure before and after nephrectomy and after renal transplantation. Clin Nephrol 6: 433–436Google Scholar
  50. 50.
    Veyrat R, Brunner HR, Manning EL, Muller AF (1967) Inhibition de l’activité de la rénine plasmatique par le potassium. J Urol Nephrol 73: 271–275Google Scholar
  51. 51.
    Wakerlin GE (1958) Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 17: 653–657PubMedGoogle Scholar
  52. 52.
    Wogermark J, Ungerstedt U, Ljungvist A (1968) Sympathetic innervation of the juxtaglomerular cells of the kidney. Circ Res 22: 149–153Google Scholar

Hypertension Due to Steroid Hormones

  1. 1.
    Aitchison J, Brown JJ, Ferris JB, Fraser R, Kay AW, Lever AF, Neville AM, Symington T, Robertson JIS (1971) Quadric analysis in the preoperative distinction between patients with and without adrenocortical tumors in hypertension with aldosterone excess and low plasma renin activity. Am Heart J 82: 660–671PubMedCrossRefGoogle Scholar
  2. 2.
    Armbruster H, Vetter W, Beckerhoff R, Nussberger J, Vetter H, Siegenthaler W (1975) Diurnal variations of plasma aldosterone in supine man: Relationship to plasma renin activity and plasma Cortisol. Acta Endocrinol 80: 95–103PubMedGoogle Scholar
  3. 3.
    Armbruster H, Vetter W, Reck G, Beckerhoff R, Siegenthaler W (1975) Severe arterial hypertension caused by chronic abuse of a topical mineralocorticoid. Int J Clin Pharmacol 12: 170–173Google Scholar
  4. 4.
    Baer LB, Sommers SC, Krakoff LR, Newton MA, Laragh JH (1970) Pseudoprimary aldosteronism: An entity distinct from true primary aldosteronism. Circ Res 26–27 (Suppl. 1): 203–219Google Scholar
  5. 5.
    Barnett IG (1970) Fluctuating Cushing’s syndrome, acute psychosis, aminoglutethimide therapy. Proc R Soc Med 63: 338–339PubMedGoogle Scholar
  6. 6.
    Baron JH, Nabarro JDN, Slater JDH, Tuffley R (1969) Metabolic studies, aldosterone secretion rate, and plasma renin after carbenoxolone sodium. Brit Med J 2: 793–795PubMedCrossRefGoogle Scholar
  7. 7.
    Bassöe HH, Emberland R, Stöa KF (1958) Fluctuating steroid excretion in Cushing’s syndrome. Acta Endocrinol 28: 163–168PubMedGoogle Scholar
  8. 8.
    Bayliss RIS, Edwards OM, Starer F (1970) Complications of adrenal venography. Brit J Radiol 43: 531–533PubMedCrossRefGoogle Scholar
  9. 9.
    Beevers DG, Brown JJ, Ferris JB, Fraser R, Lever AF, Robertson JIS, Tree M (1976) Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence of tertiary hyperaldosteronism. Q J Med 45: 401–410PubMedGoogle Scholar
  10. 10.
    Biglieri EG, Herron MA, Brust N (1966) 17-Hydroxylation deficiency in man. J Clin Invest 45: 1946–1954Google Scholar
  11. 11.
    Biglieri EG, Schambelan M, Brust N, Chang B, Hogan M (1974) Plasma aldosterone concentration. Further characterization of aldosterone-producing adenomas. Circ Res 34–35 (Suppl. 1): 183–189Google Scholar
  12. 12.
    Biglieri EG, Schambelan M, Slaton PE (1969) Effect of adrenocorticotropin on desoxycorticosterone, corticosterone, and aldosterone excretion. J Clin Endocrinol 29: 1090–1101CrossRefGoogle Scholar
  13. 13.
    Biglieri EG, Stockigt JR, Schambelan M (1970) A preliminary evaluation for primary aldosteronism. Arch Intern Med 126: 1004–1007PubMedCrossRefGoogle Scholar
  14. 14.
    Biglieri EG, Stockigt JR, Schambelan M (1972) Adrenal mineralocorticoids causing hypertension. Am J Med 52: 623–632PubMedCrossRefGoogle Scholar
  15. 15.
    Birke G, Diczfalusy E, Plantin L-O (1956) Fluctuation in the excretion of adrenocortical steroids in a case of Cushing’s syndrome. J Clin Endocrinol 16: 286–290CrossRefGoogle Scholar
  16. 16.
    Blair RJ, Beierwaltes WH, Lieberman LM, Boyd CM, Counsell RE, Weinhold PA, Varma VM (1971) Radiolabeled cholesterol as an adrenal scanning agent. J Nucl Med 12: 176–182Google Scholar
  17. 17.
    Brooks RV, Jeffcoat SL, London DR, Prunty FTG, Smith PM (1966) Intermittent Cushing’s syndrome with anomalous response to dexamethasone. J Endocrinol 36: 53–61PubMedCrossRefGoogle Scholar
  18. 18.
    Brown JJ, Chinn RH, Davies DL, Düsterdieck G, Fraser R, Lever AF, Robertson JIS, Tree A, Wiseman A (1968) Plasma electrolytes, renin, and aldosterone in the diagnosis of primary aldosteronism. Lancet 2: 55–59CrossRefGoogle Scholar
  19. 19.
    Brown JJ, Davies DL, Ferris JB, Fraser R, Haywood E, Lever AF, Robertson JIS (1972) Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Brit Med J 2: 729–734PubMedCrossRefGoogle Scholar
  20. 20.
    Brown RD, Van Loon GR, Orth DN, Liddle DW (1973) Cushing’s disease with periodic hormogenesis: One explanation for paradoxical response to dexamethasone. J Clin Endocrinol 36: 445–451CrossRefGoogle Scholar
  21. 21.
    Bucht H (1962) Percutaneous catheterisation of the left adrenal vein in man. Scand J Clin Invest 14 (Suppl. 64): 27–38Google Scholar
  22. 22.
    Bucht H, Bergstrom J, Lindholmer B, Wijnbladh H, Hokfelt B (1964) Catheterisation of the left adrenal vein for contrast injection and steroid analysis in a case of Conn’s syndrome. Acta Med Scand 176: 233–241PubMedCrossRefGoogle Scholar
  23. 23.
    Cain JP, Tuck ML, Williams GH, Dluhy RG, Rosenoif SH (1972) The regulation of aldosterone secretion in primary aldosteronism. Am J Med 53: 627–637PubMedCrossRefGoogle Scholar
  24. 24.
    Carmalt MHB, Dalton GA, Fletcher RF, Smith WT (1977) The treatment of Cushing’s disease by transsphenoidal hypophysectomy. Q J Med 46: 119–134PubMedGoogle Scholar
  25. 25.
    Child DF, Burke CW, Burley DM, Rees LH, Fraser TR (1970) Drug control of Cushing’s syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol 82: 330–334Google Scholar
  26. 26.
    Christy NP (1971) Iatrogenic Cushing’s syndrome. In: Christy NP (ed) The Human Adrenal Cortex. Harper & Row, New York, pp 395–425Google Scholar
  27. 27.
    Conn JW (1955) Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45: 3–17PubMedGoogle Scholar
  28. 28.
    Conn JW (1967) The evolution of primary aldosteronism, 1954–1967. Harvey Lecture 62: 257–291Google Scholar
  29. 29.
    Conn JW, Cohen EL, Herwig KR (1976) The dexamethasone-modified adrenal scintiscan in hyporeninemic aldosteronism (tumor versus hyperplasia). A comparison with adrenal venography and adrenal venous aldosterone. J Lab Clin Med 88: 841–856PubMedGoogle Scholar
  30. 30.
    Conn JW, Cohen EL, Rovner DR, Nesbit RM (1965) Normokalemic primary aldosteronism. A detectable cause of curable “essential” hypertension. JAMA 193: 200–206PubMedGoogle Scholar
  31. 31.
    Conn JW, Knopf RF, Nesbit RM (1964) Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107: 159–172PubMedCrossRefGoogle Scholar
  32. 32.
    Conn JW, Rovner DR, Cohen EL (1968) Licorice-induced pseudoaldosteronism. JAMA 205: 492–496PubMedCrossRefGoogle Scholar
  33. 33.
    Connolly CK, Gore MBR, Stanley N, Wills MR (1968) Single-dose dexamethasone suppression in normal subjects and in hospital patients. Brit Med J 2: 665–667Google Scholar
  34. 34.
    Cope CL (1956) Diagnostic use of adrenal inhibition in Cushing’s syndrome. Brit Med J 2: 193–197PubMedCrossRefGoogle Scholar
  35. 35.
    Crane MG, Harris J J (1966) Deoxycorticosterone secretion rates in hyperadrenocorticism. J Clin Endocrinol 26: 1135–1143CrossRefGoogle Scholar
  36. 36.
    Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestations. Bull Johns Hopkins Hosp 50: 137–195Google Scholar
  37. 37.
    Danforth DN, Orlando MM, Bartter FC, Javadpour N (1977) Renal changes in primary aldosteronism. J Urol 117: 140–144PubMedGoogle Scholar
  38. 38.
    David DS, Berkowitz JS (1969) Ocular effects of topical and systemic corticosteroids. Lancet 2: 149–151PubMedCrossRefGoogle Scholar
  39. 39.
    Davies WW, Newsome HH, Wright LD, Hammond WG, Easton J, Bartter FC (1967) Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia, and suppressed renin activity. Am J Med 42: 642–647CrossRefGoogle Scholar
  40. 40.
    Del Greco F, Dolkart R, Skom J, Method H (1966) Association of accelerated (malignant) hypertension in a patient with primary aldosteronism. J Clin Endocrinol 26: 808–814CrossRefGoogle Scholar
  41. 41.
    Deller JJ, Wegienka LC, Conte NF, Rosner JM, Forsham PH (1975) Testosterone metabolism in idiopathic hirsutism. Ann Intern Med 63: 369–376Google Scholar
  42. 42.
    Dige-Petersen H, Munkner T, Fogh J, Blichert-Toft M, Lund JO (1975)131I-19-iodocholesterol scintigraphy of the adrenal cortex. Acta Endocrinol 80: 81–94Google Scholar
  43. 43.
    Distler A, Barth C, Roscher S, Vescei P, Dhom G, Wolif HP (1969) Hochdruck und Aldosteronismus bei solitären Adenomen und bei nodulärer Hyper-plasie der Nebennierenrinde. Klin Wschr 47: 688–695PubMedCrossRefGoogle Scholar
  44. 44.
    Eagan RT, Page MI (1971) Adrenal insufficiency following bilateral adrenal venography. JAMA 215: 115–116PubMedCrossRefGoogle Scholar
  45. 45.
    Ehrlich EN, Domínguez OV, Samuels LT, Lynch D, Oberhelman H, Warner NE (1963) Aldosteronism and precocious puberty due to an ovarian androblastoma (Sertoli cell tumor). J Clin Endocrinol 23: 358–367CrossRefGoogle Scholar
  46. 46.
    Ferris JB, Brown JJ, Fraser R, Haywood E, Davies DL, Kay AW, Lever AF, Robertson JIS, Owen K, Peart WS (1975) Results of adrenal surgery in pa-tients with hypertension, aldosterone excess, and low plasma renin concentration. Brit Med J 1: 135–138CrossRefGoogle Scholar
  47. 47.
    Ferris JB, Brown JJ, Fraser R, Kay AW, Neville AM O’Muircheartaigh IG, Robertson JIS, Symington T, Lever AF (1970) Hypertension with aldosterone excess and low plasma renin: Preoperative distinction between patients with and without adrenocortical tumor. Lancet 2: 995–1000Google Scholar
  48. 48.
    Fisher EE, Turner FA, Horton R (1971) Remission of primary hyperaldosteronism after adrenal venography. N Engl J Med 285: 334–336PubMedCrossRefGoogle Scholar
  49. 49.
    Fishman LM, Küchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT (1968) Incidence of primary aldosteronism in uncomplicated “essential” hypertension. JAMA 205: 497–502PubMedCrossRefGoogle Scholar
  50. 50.
    Flanagan MJ, McDonald JH (1967) Heterotopic adrenocortical adenoma producing primary aldosteronism. J Urol 98: 133–139PubMedGoogle Scholar
  51. 51.
    Fleisher DS (1967) Pituitary-adrenal responsiveness after corticosteroid therapy in children with nephrosis. J Pediat 70: 54–59PubMedCrossRefGoogle Scholar
  52. 52.
    Forman B, Antar NA, Touloukian RJ, Mulrow PJ, Genel M (1974) Localization of a metastatic adrenal carcinoma using 131 I-19-iodocholesterol. J Nucl Med 15: 332–334PubMedGoogle Scholar
  53. 53.
    French FS, Macfie JA, Baggett B, Williams TF, Van Wyk J (1969) Cushing’s syndrome with a paradoxical response to dexamethasone. Am J Med 47: 619–624PubMedCrossRefGoogle Scholar
  54. 54.
    Fukuchi S, Takenouchi T, Nakagima K, Watanabe H, Sugita A (1975) Location of aldosterone-producing adenomas by the determination of plasma aldosterone in adrenal vein or renal vein blood. Cli Sci 49: 187–192Google Scholar
  55. 55.
    Ganguly A, Melada GA, Luetscher JA, Dowdy AJ (1973) Control of plasma aldosterone in primary aldosteronism. Distinction between adenoma and hyperplasia. J Clin Endocrinol 37: 765–775CrossRefGoogle Scholar
  56. 56.
    George JM, Wright LW, Bell NH, Bartter FC (1970) The syndrome of primary aldosteronism. Am J Med 48: 343–356PubMedCrossRefGoogle Scholar
  57. 57.
    Green JRB, Van’t Hoff W (1975) Cushing’s syndrome with fluctuation due to adrenal adenoma. J Clin Endocrinol 41: 235–240Google Scholar
  58. 58.
    Greminger P, Vetter W, Zimmermann K, Beckerhoff R, Siegenthaler W (1977) Primäre und sekundäre Hypertonie in einem poliklinischen Patientengut. Schweiz Med Wschr 107: 605–609PubMedGoogle Scholar
  59. 59.
    Gulati PD, Malik GB, Vaishnava H (1973) Alternate-day steroid therapy in adult nephrotics. J Med 4: 266–275PubMedGoogle Scholar
  60. 60.
    Hankin ME, Theile HM, Steinbeck AW (1977) An evaluation of laboratory tests for the detection and differential diagnosis of Cushing’s syndrome. Clin Endocrinol (Oxford) 6: 185–196CrossRefGoogle Scholar
  61. 61.
    Harter JG, Reddy WJ, Thorn GW (1963) Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 269: 591–596PubMedCrossRefGoogle Scholar
  62. 62.
    Heiman WG, Freiberger RH (1960) A vascular necrosis of the femoral and humeral heads after high-dosage corticosteroid therapy. N Engl J Med 263: 672–675CrossRefGoogle Scholar
  63. 63.
    Helber A, Dvorak K, Winkelmann W, Meurer KA, Würz H, Dickmans A (1975) 13J-Cholesterin-Szintigraphie der Nebennieren. Erfahrungen bei verschiedenen Nebennierenerkrankungen, insbesondere einseitigen Nebennierentumoren. Dtsch Med Wschr 100: 2524–2527Google Scholar
  64. 64.
    Hellman L, Weitzmann ED, Roffwarg H, Fukushima DK, Gallagher TF (1970) Cortisol is secreted episodically in Cushing’s syndrome. J Clin Endocrinol 30: 686–689CrossRefGoogle Scholar
  65. 65.
    Hoet J J, Molineaux L (1960) Conn’s syndrome: The effect of amphenone. Acta Endocrinol 33: 375–387PubMedGoogle Scholar
  66. 66.
    Hogan MJ, McRae J, Schambelan M, Biglieri EG (1976) Location of aldosterone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med 294: 410–414PubMedCrossRefGoogle Scholar
  67. 67.
    Hutter AM, Kayhoe DE (1966) Adrenal cortical carcinoma. Results of treatment with o,p’-DDD in 138 patients. Am J Med 41: 581–592PubMedCrossRefGoogle Scholar
  68. 68.
    Jailer JW, Van de Wiele R, Christy NP, Liebermann S (1959) Studies in Cushing’s syndrome. III. Urinary 17-ketosteroids in patients with bilateral adrenal cortical hyperplasia. J Clin Invest 38: 357–365Google Scholar
  69. 69.
    James VHT (1961) The excretion of individual 17-oxosteroids in Cushing’s syndrome. J Endocrinol 23: 119–127PubMedCrossRefGoogle Scholar
  70. 70.
    James VHT, Landau J, Wynn V (1965) Oral and intravenous suppression tests in the diagnosis of Cushing’s syndrome. J Endrocrinol 36: 515–524CrossRefGoogle Scholar
  71. 71.
    Jorgenson H, Norman N, Sundsfjord JA (1975) Scintigraphy with 131I-19-iodocholesterol in adrenal disease. Acta Med Scand 197: 345–351CrossRefGoogle Scholar
  72. 72.
    Jergenson H, Stiris G (1974) Hypertensive crisis followed by adrenocortical insufficiency after unilateral adrenal phlebography in a patient with Cushing’s syndrome. Acta Med Scand 196: 141–143CrossRefGoogle Scholar
  73. 73.
    Kahn PC, Kelleher MD, Egdahl RH, Melby JC (1971) Adrenal arteriography and venography in primary aldosteronism. Radiology 101: 71–78PubMedGoogle Scholar
  74. 74.
    Kalsner S (1969) Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ Res 24: 383–395PubMedGoogle Scholar
  75. 75.
    Kaplan NM (1963) Primary aldosteronism with malignant hypertension. N Engl J Med 269: 1282–1286PubMedCrossRefGoogle Scholar
  76. 76.
    Kaplan NM (1967) Hypokalemia in the hypertensive patient. Ann Intern Med 66: 1079–1090PubMedGoogle Scholar
  77. 77.
    Kaplan NM (1969) Commentary on incidence of primary aldosteronism: Current estimations based on objective data. Arch Intern Med 123: 152–154PubMedCrossRefGoogle Scholar
  78. 78.
    Katz FH (1967) Primary aldosteronism with sup-pressed plasma renin activity due to bilateral nodular adrenocortical hyperplasia. Ann Intern Med 67: 1035–1042PubMedGoogle Scholar
  79. 79.
    Kem DC, Weinberger MH, Mayes DM, Nugent CA (1971) Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128: 380–386PubMedCrossRefGoogle Scholar
  80. 80.
    Kem DC, Weinberger MH, Gomez-Sanchez C, Higgins JR, Kramer NJ (1976) The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. J Lab Clin Med 88: 261–270PubMedGoogle Scholar
  81. 81.
    Krakoff L (1973) Measurement of plasma renin substrate by radioimmunoassay of angiotensin I: Concentration in syndromes associated with steroid excess. J Clin Endocrinol 37: 110–117CrossRefGoogle Scholar
  82. 82.
    Krakoff L, Nicolis G, Amsel B (1975) Pathogenesis of hypertension in Cushing’s syndrome. Am J Med 58: 216–220PubMedCrossRefGoogle Scholar
  83. 83.
    Krieger DT, Amorosa L, Linick F (1975) Cyproheptadine-induced remission of Cushing’s disease. N Engl J Med 293: 893–896PubMedCrossRefGoogle Scholar
  84. 84.
    Laidlaw JC, Yerndt ER, Gornall AG (1960) Hypertension caused by renal artery occlusion simulating primary aldosteronism. Metabolism 9: 612–623PubMedGoogle Scholar
  85. 85.
    Liddle GW (1960) Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing’s syndrome. J Clin Endocrinol 20: 1539–1560CrossRefGoogle Scholar
  86. 86.
    Liddle GW, Bledsoe T, Coppage WS (1963) A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 76: 199–213Google Scholar
  87. 87.
    Lieberman LM, Beierwaltes WH, Conn JW, Ansari AN, Nishiyama HN (1971) Diagnosis of adrenal disease by visualization of human adrenal glands with 131I-19-iodocholesterol. N Engl J Med 285: 1387–1393PubMedCrossRefGoogle Scholar
  88. 88.
    Linn JE, Bowdoin B, Farmer A, Meador CK (1967) Observations and comments on failure of dexamethasone suppression. N Engl J Med 277: 403–405PubMedCrossRefGoogle Scholar
  89. 89.
    Lufkin EG, Katz FH, Hernán RH (1972) Primary aldosteronism due to hyperplasia of zona glomeru- losa: Failure of suppression by DOCA or stimulation by angiotensin. Am J Med Sci 264: 367–374PubMedCrossRefGoogle Scholar
  90. 90.
    MacGregor RR, Sheagren JN, Lipsett MB, Wolff SM (1969) Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease, and steroid side effects. N Engl J Med 280: 1427–1431PubMedCrossRefGoogle Scholar
  91. 91.
    McEnery PT, Gonzalez LL, Martin LW, West CD (1973) Growth and development of children with renal transplants. Use of alternate-day steroid therapy. J Pediat 83: 806–814PubMedCrossRefGoogle Scholar
  92. 92.
    McKenzie AD, Mcintosh HW (1965) Hyperpigmentation and pituitary tumor as sequelae of the surgical treatment of Cushing’s syndrome. Am J Surg 110: 135–141PubMedCrossRefGoogle Scholar
  93. 93.
    Melby JC (1971) Therapeutic possibilities in Cushing’s syndrome. N Engl J Med 285: 288–289PubMedCrossRefGoogle Scholar
  94. 94.
    Melby JC, Dale SL, Wilson TE (1971) 18-Hydroxydeoxycorticosterone in human hypertension. Circ Res 28–29 (Suppl. 2 ): 143–152Google Scholar
  95. 95.
    Melby JC, Spark RF, Dale SL, Egdahl RH, Kahn PC (1967) Diagnosis and localization of aldosterone- producing adenomas by adrenal vein catheterization. N Engl J Med 277: 1050–1056PubMedCrossRefGoogle Scholar
  96. 96.
    Mendlowitz M, Gitlow S, Naftchi N (1958) Work of digital vasoconstriction produced by infused norepinephrine in Cushing’s syndrome. J Appl Physiol 13: 252–256PubMedGoogle Scholar
  97. 97.
    Miura K, Aida M, Mihara A, Kato K, Ojima M, Demura R, Demura H, Okuyama M (1975) Treatment of Cushing’s disease with reserpine and pituitary irradiation. J Clin Endocrinol 41: 511–526CrossRefGoogle Scholar
  98. 98.
    Moore TJ, Dluhy RG, Williams GH, Cain JP (1976) Nelson’s syndrome: Frequency, prognosis, and effect of prior pituitary irradiation. Ann Intern Med 85: 731–734PubMedGoogle Scholar
  99. 99.
    Nelson DH, Meakin JW, Dealy JB (1958) ACTH- producing tumor of the pituitary gland. N Engl J Med 259: 161–164PubMedCrossRefGoogle Scholar
  100. 100.
    Neville AM, Symington T (1966) Pathology of primary aldosteronism. Cancer 19: 1854–1868PubMedCrossRefGoogle Scholar
  101. 101.
    Nichols T, Nugent CA, Tyler FH (1968) Steroid lab-oratory tests in the diagnosis of Cushing’s syndrome. Am J Med 45: 116–128CrossRefGoogle Scholar
  102. 102.
    Nicholls MG, Espiner EA, Hughes A, Ross J, Stewart DT (1975) Primary aldosteronism. A study in contrast. Am J Med 59: 334–342PubMedCrossRefGoogle Scholar
  103. 103.
    Nicolis GL, Mitty HA, Modlinger RS, Gabrilove JL (1972) Percutaneous adrenal venography. A clinical study of 50 patients. Ann Intern Med 76: 899–909PubMedGoogle Scholar
  104. 104.
    Nicolis GL, Babich AM, Mitty HA, Gabrilove LJ (1974) Observation on the Cortisol content of human adrenal venous blood. J Clin Endocrinol 38: 638–645CrossRefGoogle Scholar
  105. 105.
    New MI (1970) Male pseudohermaphroditism due to 17-hydroxylase deficiency. J Clin Invest 49: 1930–1941PubMedCrossRefGoogle Scholar
  106. 106.
    Newton MA, Laragh JH (1968) Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hyper-tension, and in primary aldosteronism. J Clin Endocrinol 28: 1014–1022CrossRefGoogle Scholar
  107. 107.
    Nugent CA, Nichols T (1965) Diagnosis of Cushing’s syndrome. Arch Intern Med 116: 172–176PubMedGoogle Scholar
  108. 108.
    Nugent CA, Warner HR, Dunn JT, Tyler FH (1964) Probability theory in the diagnosis of Cushing’s syndrome. J Clin Endocrinol 24: 621–627CrossRefGoogle Scholar
  109. 109.
    Oddie CJ, Coghlan JP, Scoggins BA (1972) Plasma deoxycorticosterone levels in man with simultaneous measurement of aldosterone, corticosterone, Cortisol, and 11-deoxycortisol. J Clin Endocrinol 34: 1039–1054CrossRefGoogle Scholar
  110. 110.
    O’Neal LW, Kissane JM, Hartroft PM, Louis S (1970) The kidney in endocrine hypertension. Arch Surg 100: 498–505PubMedGoogle Scholar
  111. 111.
    Orth DN, Liddle GW (1971) Results of treatment in 108 patients with Cushing’s disease. N Engl J Med 285: 244–247CrossRefGoogle Scholar
  112. 112.
    Padfield PL, Allison MEM, Brown JJ, Ferris JB, Fraser R, Lever AF, Luke RG, Robertson JIS (1975) Response of plasma aldosterone to fludrocortisone in primary hyperaldosteronism and other forms of hypertension. Clin Endocrinol 4: 493–500CrossRefGoogle Scholar
  113. 113.
    Pearse AGE (1969) The cytochemistry and ultra-structure of polypeptide hormone-producing cells of the APUD series and the embryologie, physiologic, and pathologic implications of the concept. J Histochem Cytochem 17: 303–313PubMedCrossRefGoogle Scholar
  114. 114.
    Ragan C (1953) Corticotropin, cortisone, and related steroids in clinical medicine. Bull NY Acad Med 29: 355–376Google Scholar
  115. 115.
    Reed WP, Lucas ZJ, Cohn R (1970) Alternate-day prednisone therapy after renal transplantation. Lancet 1: 747–749PubMedCrossRefGoogle Scholar
  116. 116.
    Reuter SR, Blair AJ, Schteingart DE, Bookstein J J (1967) Adrenal venography. Radiology 89: 805–814PubMedGoogle Scholar
  117. 117.
    Ross EJ, Marshall-Jones P, Friedman M (1966) Cushing’s syndrome: Diagnostic criteria. QJ Med 35: 149–193Google Scholar
  118. 118.
    Sarkar SD, Beierwaltes WH, Ice RD, Besmadjian, Hetzel KR, Kennedy WP, Mason MM (1975) A new and superior adrenal scanning agent, NP-59. J Nucl Med 16: 1038–1042Google Scholar
  119. 119.
    Schambelan M, Brust NL, Chang CF, Slater KL, Biglieri EG (1976) Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. J Clin Endocrinol 43: 115–131CrossRefGoogle Scholar
  120. 120.
    Schambelan M, Slaton PE, Biglieri EG (1971) Mineralocorticoid production in hyperadrenocorticism. Role in pathogenesis of hypokalemic alkalosis. Am J Med 51: 299–303PubMedCrossRefGoogle Scholar
  121. 121.
    Scoggins BA, Oddie CJ, Hare WSC, Coghlan JP (1972) Preoperative latéralisation of aldosterone- producing tumors in primary aldosteronism. Ann Intern Med 76: 891–897PubMedGoogle Scholar
  122. 122.
    Scott HW, Liddle GW, Harris AP, Forster JH (1962) Diagnosis and treatment of Cushing’s syndrome. Ann Surg 155: 696–710CrossRefGoogle Scholar
  123. 123.
    Seabold JE, Cohen EL, Beierwaltes WH, Hinerman DL, Nishiyama RH, Bookstein JJ, Ice RD, Balachandran S (1976) Adrenal imaging with 131I-19-iodocholesterol in the diagnostic evaluation of patients with primary aldosteronism. J Clin Endocrinol 42: 41–51CrossRefGoogle Scholar
  124. 124.
    Sederberg-Olsen P, Binder C, Kehlet H, Neville AM, Nielsen LM (1973) Episodic variation in plasma corticosteroids in subjects with Cushing’s syndrome of differing etiology. J Clin Endocrin Metab 36: 906–910CrossRefGoogle Scholar
  125. 125.
    Salti IS, Stiefel M, Ruse JL, Laidlaw JC (1969) Non- tumorous “primary” aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism). Can Med Assoc J 101: 1–10PubMedGoogle Scholar
  126. 126.
    Siegel RR, Luke RG, Hellebusch AA (1972) Reduction of toxicity of corticosteroid therapy after renal transplantation. Am J Med 53: 159–169PubMedCrossRefGoogle Scholar
  127. 127.
    Slaton PE, Schambelan M, Biglieri EG (1969) Stimulation and suppression of aldosterone secretion in patients with an aldosterone-producing adenoma. J Clin Endocrinol 29: 239–250CrossRefGoogle Scholar
  128. 128.
    Spark RF, Kettyle WR, Eisenberg H (1974) Cortisol dynamics in the adrenal venous effluent. J Clin Endocrinol 39: 305–310CrossRefGoogle Scholar
  129. 129.
    Soyka LF (1967) Treatment of the nephrotic syndrome in childhood. Use of an alternate-day prednisone regimen. Am J Dis Child 113: 693–701PubMedGoogle Scholar
  130. 130.
    Starer F (1965) Percutaneous supraadrenal venography. Brit J Radiol 38: 675–681PubMedCrossRefGoogle Scholar
  131. 131.
    Streeten DHP, Stevenson CT, Dalakos TG, Nicholas J J, Dennick LG, Fellerman H (1969) The diagnosis of hypercortisolism. Biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives. J Clin Endocrinol 29: 1191–1211CrossRefGoogle Scholar
  132. 132.
    Taylor HC, Sachs CR, Bravo EL (1976) Primary aldosteronism: Remission and development of adrenal insufficiency after adrenal venography. Ann Intern Med 85: 207–209PubMedGoogle Scholar
  133. 133.
    Todesco S, Terrible V, Borsatti A, Mantero F (1975) Primary aldosteronism due to a malignant ovarian tumor. J Clin Endocrinol 41: 809–819CrossRefGoogle Scholar
  134. 134.
    Tourniaire J, Orgiazzi J, Riviere JF, Rousset H (1971) Repeated plasma Cortisol determinations in Cushing’s syndrome due to adrenocortical adenoma. J Clin Endocrinol 32: 666–668CrossRefGoogle Scholar
  135. 135.
    Velayos EE, Leidholt JD, Smyth CJ, Priest R (1966) Arthropathy associated with steroid therapy. Ann Intern Med 64: 759–771Google Scholar
  136. 136.
    Vetter H, Berger M, Armbruster H, Siegenthaler W, Werning C, Vetter W (1974) Episodic secretion of aldosterone in primary aldosteronism: Relationship to Cortisol. Clin Endocrinol 3: 41–48CrossRefGoogle Scholar
  137. 137.
    Vetter H, Strass R, Bayer J-M, Beckerhoff R, Armbruster H, Vetter W (1977) Short-term fluctuations in plasma Cortisol in Cushing’s syndrome. Clin Endocrinol 6: 1–4CrossRefGoogle Scholar
  138. 138.
    Vetter H, Vetter W (1975) Regulation of aldosterone secretion in primary aldosteronism. Horm Metab Res 7: 418–424PubMedCrossRefGoogle Scholar
  139. 139.
    Vetter H, Vetter W, Beckerhoff R, Sobbe A, Nussberger J, Witassek F, Siegenthaler W (1975) Primärer Aldosteronismus: Diagnose, Seitenlokalisation, und Regulation der Hormonsekretion. Schweiz Med Wschr 105: 1695–1698PubMedGoogle Scholar
  140. 140.
    Vetter W, Vetter H, Nussberger J, Witassek F, Beckerhoff R, Pouliadis G, Braun KP, Sobbe A, Furrer J, Siegenthaler W (1976) Primärer Aldosteronismus. Schweiz Med Wschr 106: 469–474PubMedGoogle Scholar
  141. 141.
    Vetter W, Vetter H, Beckerhoff R, Witassek F, Pouliadis G, Furrer J, Siegenthaler W (1976) Endokrine Hypertonie bei primärem Aldosteronismus und Cushing-Syndrom. Schweiz Med Wschr 106: 1773–1777PubMedGoogle Scholar
  142. 142.
    Vetter W, Vetter H, Beckerhoff R, Würsten D, Siegenthaler W (1973) Nicht dauerhafte Remission des Hyperkortizismus durch Cyproheptadin bei einer Patientin mit Cushing-Syndrom. Schweiz Med Wschr 106: 1320–1322Google Scholar
  143. 143.
    Walker AE, Adamkiewicz JJ (1964) Pseudotumor cerebri associated with prolonged corticosteroid therapy. JAMA 188: 779–784PubMedGoogle Scholar
  144. 144.
    Weichert RF (1970) The neural ectodermal origin of the peptide secreting endocrine glands. Am J Med 49: 232–241PubMedCrossRefGoogle Scholar
  145. 145.
    Weiss FR, Rayyis SS, Nelson DH, Bethune JE (1969) Evaluation of stimulation and suppression tests in the etiological diagnosis of Cushing’s syndrome. Ann Intern Med 71: 941–949PubMedGoogle Scholar
  146. 146.
    Werning C, Stadelmann O, Miederer SE, Vetter W, Schweikert HU, Stiel D, Siegenthaler W (1971) Der Einfluß einer Carbenoxolon-Therapie auf das Renin-Angiotensin-Aldosteron-System. Klin Wschr 49: 1285–1289PubMedCrossRefGoogle Scholar
  147. 147.
    Woods JW, Hill C, Liddle GW, Stant EG, Michelakis AM, Brill AB (1969) Effect of an adrenal inhibitor in hypertensive patients with suppressed renin. Arch Intern Med 123: 366–370PubMedCrossRefGoogle Scholar
  148. 148.
    Yune HY, Klatte EC, Grim CE, Weinberger MH, Donohue JP, Yum MN, Wellman NH (1976) Ra-diology in primary aldosteronism. Am J Roentgenol 127: 761–767Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1982

Authors and Affiliations

  • H. Vetter
  • W. Vetter

There are no affiliations available

Personalised recommendations